Anti-drug antibodies, auto-antibodies and biotherapy in psoriasis;Anticorps anti-médicament, auto-anticorps et traitements biologiques du psoriasis

Annales de Dermatologie et de Venereologie

Volumn 139, Issue SUPPL.2, 2012, Pages

  Jullien, D ^a,b,c  

^a UNIVERSITÉ DE LYON   (France)

^b UNIVERSITÉ LYON 1   (France)

^c EDOUARD HERRIOT HOSPITAL   (France)

Author keywords

Anti adalimumab; Anti etanercept; Anti infliximab; Anti TNF ; Anti ustekinumab; Antinuclear antibodies; Immunogenicity; Neutralizing antibody; Psoriasis

Indexed keywords

ADALIMUMAB; ANTINUCLEAR ANTIBODY; AUTOANTIBODY; DRUG ANTIBODY; ETANERCEPT; HYBRID PROTEIN; INFLIXIMAB; MONOCLONAL ANTIBODY; NEUTRALIZING ANTIBODY; TUMOR NECROSIS FACTOR ALPHA ANTIBODY; USTEKINUMAB;

ANAPHYLAXIS; ARTICLE; AUTOIMMUNE DISEASE; AUTOIMMUNITY; BIOLOGICAL THERAPY; CROHN DISEASE; DRUG EFFICACY; DRUG SAFETY; HUMAN; IMMUNE RESPONSE; IMMUNOGENICITY; PSORIASIS; RHEUMATOID ARTHRITIS; SKIN DISEASE; TREATMENT FAILURE; ULCERATIVE COLITIS; VASCULITIS;

ANTIBODY FORMATION; AUTOANTIBODIES; DRUG RESISTANCE; HUMANS; IMMUNOTHERAPY; PSORIASIS;

EID: 84860470612     PISSN: 01519638     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0151-9638(12)70112-6     Document Type: Article

References (66)

1. P. Stas, and I. Lasters Immunogénicité de protéines d'intérêt thérapeutique: les anticorps monoclonaux thérapeutiques Med Sci (Paris) 25 2009 1070 1077
2. J.F. Nicolas, N. Chamchick, J. Thivolet, J. Wijdenes, P. Morel, and J.P. Revillard CD4 antibody treatment of severe psoriasis Lancet 338 1991 321
3. J. Prinz, O. Braun-Falco, M. Meurer, P. Daddona, C. Reiter, and P. Rieber Chimaeric CD4 monoclonal antibody in treatment of generalised pustular psoriasis Lancet 338 1991 320 321
4. K. Bendtzen, M. Ainsworth, C. Steenholdt, O.O. Thomsen, and J. Brynskov Individual medicine in inflammatory bowel disease: monitoring bioavailability, pharmacokinetics and immunogenicity of anti-tumour necrosis factor-alpha antibodies Scand J Gastroenterol 44 2009 774 781
5. E.C. Ebert, K.M. Das, V. Mehta, and C. Rezac Non-response to infliximab may be due to innate neutralizing anti-tumour necrosis factoralpha antibodies Clin Exp Immunol 154 2008 325 331
6. G.M. Bartelds, C.A. Wijbrandts, M.T. Nurmohamed, S. Stapel, W.F. Lems, and L. Aarden Clinical response to adalimumab: relationship to anti-adalimumab antibodies and serum adalimumab concentrations in rheumatoid arthritis Ann Rheum Dis 66 2007 921 926 (Pubitemid 46999794)
7. R.N. Maini, F.C. Breedveld, J.R. Kalden, J.S. Smolen, D. Davis, and J.D. Macfarlane Therapeutic efficacy of multiple intravenous infusions of anti-tumor necrosis factor alpha monoclonal antibody combined with low-dose weekly methotrexate in rheumatoid arthritis Arthritis Rheum 41 1998 1552 1563 (Pubitemid 28459913)
8. E. Ducourau, D. Mulleman, G. Paintaud, D.C. Miow Lin, F. Lauferon, and D. Ternant Antibodies toward infliximab are associated with low infliximab concentration at treatment initiation and poor infliximab maintenance in rheumatic diseases Arthritis Res Ther 13 2011 R105
9. S.B. Hanauer, B.G. Feagan, G.R. Lichtenstein, L.F. Mayer, S. Schreiber, and J.F. Colombel Maintenance infliximab for Crohn's disease: the ACCENT I randomised trial Lancet 359 2002 1541 1549 (Pubitemid 34621118)
10. S. Vermeire, M. Noman, G. Van Assche, F. Baert, G. D'Haens, and P. Rutgeerts Effectiveness of concomitant immunosuppressive therapy in suppressing the formation of antibodies to infliximab in Crohn's disease Gut 56 2007 1226 1231 (Pubitemid 47300423)
11. R.J. Farrell, M. Alsahli, Y.T. Jeen, K.R. Falchuk, M.A. Peppercorn, and P. Michetti Intravenous hydrocortisone premedication reduces antibodies to infliximab in Crohn's disease: a randomized controlled trial Gastroenterology 124 2003 917 924 (Pubitemid 36389794)
12. E. Adisen, A. Aral, C. Aybay, and M.A. Gurer Anti-infliximab antibody status and its relation to clinical response in psoriatic patients: A pilot study J Dermatol 37 2010 708 713
13. K. Bendtzen, P. Geborek, M. Svenson, L. Larsson, M.C. Kapetanovic, and T. Saxne Individualized monitoring of drug bioavailability and immunogenicity in rheumatoid arthritis patients treated with the tumor necrosis factor α inhibitor infliximab Arthritis Rheum 54 2006 3782 3789 (Pubitemid 44955878)
14. E.V. Loftus Jr., X. Pan, P. Zurawski, P. Mulani, and J. Chao Adalimumab real-world dosage patterns and predictors of weekly dosing: patients with Crohn's disease in the United States J Crohns Colitis 5 2011 550 554
15. S.B. Hanauer, C.L. Wagner, M. Bala, L. Mayer, S. Travers, and R.H. Diamond Incidence and importance of antibody responses to infliximab after maintenance or episodic treatment in Crohn's disease Clin Gastroenterol Hepatol 2 2004 542 553 (Pubitemid 38834038)
16. A.B. Gottlieb, R. Evans, S. Li, L.T. Dooley, C.A. Guzzo, and D. Baker Infliximab induction therapy for patients with severe plaquetype psoriasis: a randomized, double-blind, placebo-controlled trial J Am Acad Dermatol 51 2004 534 542 (Pubitemid 39278071)
17. A. Menter, S.R. Feldman, G.D. Weinstein, K. Papp, R. Evans, and C. Guzzo A randomized comparison of continuous vs. intermittent infliximab maintenance regimens over 1 year in the treatment of moderate-to-severe plaque psoriasis J Am Acad Dermatol 56 2007 31e1 31e15
18. th Annual congress of the European Academy of Dermatology and Venereology;6-10/10/2010 Gothenburg 2010 P563
19. M. Svenson, P. Geborek, T. Saxne, and K. Bendtzen Monitoring patients treated with anti-TNF-alpha biopharmaceuticals: assessing serum infliximab and anti-infliximab antibodies Rheumatology (Oxford) 46 2007 1828 1834 (Pubitemid 350168300)
20. G.M. Bartelds, C.A. Wijbrandts, M.T. Nurmohamed, G.J. Wolbink, N. de Vries, and P.P. Tak Anti-adalimumab antibodies in rheumatoid arthritis patients are associated with interleukin-10 gene polymorphisms Arthritis Rheum 60 2009 2541 2542
21. K. Reich, F.O. Nestle, K. Papp, J.P. Ortonne, R. Evans, and C. Guzzo Infliximab induction and maintenance therapy for moderateto-severe psoriasis: a phase III, multicentre, double-blind trial Lancet 366 2005 1367 1374 (Pubitemid 41443403)
22. S. Tyring, K.B. Gordon, Y. Poulin, R.G. Langley, A.B. Gottlieb, and M. Dunn Long-term safety and efficacy of 50 mg of etanercept twice weekly in patients with psoriasis Arch Dermatol 143 2007 719 726 (Pubitemid 46955730)
23. C.L. Leonardi, A.B. Kimball, K.A. Papp, N. Yeilding, C. Guzzo, and Y. Wang Efficacy and safety of ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with psoriasis: 76-week results from a randomised, double-blind, placebo-controlled trial (PHOENIX 1) Lancet 371 2008 1665 1674 (Pubitemid 351671883)
24. K.A. Papp, R.G. Langley, M. Lebwohl, G.G. Krueger, P. Szapary, and N. Yeilding Efficacy and safety of ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with psoriasis: 52-week results from a randomised, double-blind, placebo-controlled trial (PHOENIX 2) Lancet 371 2008 1675 1684 (Pubitemid 351671884)
25. J.B. Quiniou, C.E.M. Griffiths, K. Gordon, P. Szapary, S. Li, and S. Fakharzadeh Reprise Du Traitement Par L'Ustekinumab après son interruption: Résultats des essais cliniques de phase I II, PHOENIX 1 et ACCEPT, menés chez des patients atteints de psoriasis modéré à sévère Ann Dermatol Venereol 138 2011 A236
26. F. Baert, M. Noman, S. Vermeire, G. Van Assche, G. D'Haens, and A. Carbonez Influence of immunogenicity on the longterm efficacy of infliximab in Crohn's disease N Engl J Med 348 2003 601 608 (Pubitemid 36204954)
27. T.R. Radstake, M. Svenson, A.M. Eijsbouts, F.H. van den Hoogen, C. Enevold, and P.L. van Riel Formation of antibodies against infliximab and adalimumab strongly correlates with functional drug levels and clinical responses in rheumatoid arthritis Ann Rheum Dis 68 2009 1739 1745
28. G.M. Bartelds, C.L. Krieckaert, M.T. Nurmohamed, P.A. van Schouwenburg, W.F. Lems, and J.W. Twisk Development of antidrug antibodies against adalimumab and association with disease activity and treatment failure during long-term follow-up JAMA 305 2011 1460 1468
29. M.K. de Vries, I.E. van der Horst-Bruinsma, M.T. Nurmohamed, L.A. Aarden, S.O. Stapel, and M.J. Peters Immunogenicity does not influence treatment with etanercept in patients with ankylosing spondylitis Ann Rheum Dis 68 2009 531 535
30. R.K. Dore, S. Mathews, J. Schechtman, W. Surbeck, D. Mandel, and A. Patel The immunogenicity, safety, and efficacy of etanercept liquid administered once weekly in patients with rheumatoid arthritis Clin Exp Rheumatol 25 2007 40 46 (Pubitemid 46477484)
31. Z. Xu, K. Seitz, A. Fasanmade, J. Ford, P. Williamson, and W. Xu Population pharmacokinetics of infliximab in patients with ankylosing spondylitis J Clin Pharmacol 48 2008 681 695 (Pubitemid 351713154)
32. A. Menter, S.K. Tyring, K. Gordon, A.B. Kimball, C.L. Leonardi, and R.G. Langley Adalimumab therapy for moderate to severe psoriasis: A randomized, controlled phase III trial J Am Acad Dermatol 58 2008 106 115 (Pubitemid 350298146)
33. L.L. Lecluse, R.J. Driessen, P.I. Spuls, E.M. de Jong, S.O. Stapel, and M.B. van Doorn Extent and clinical consequences of antibody formation against adalimumab in patients with plaque psoriasis Arch Dermatol 146 2010 127 132
34. R. Gniadecki, K. Kragballe, T.N. Dam, and L. Skov Comparison of drug survival rates for adalimumab, etanercept and infliximab in patients with psoriasis vulgaris Br J Dermatol 164 2011 1091 1096
35. K. Noiles, and R. Vender Biologic survival J Drugs Dermatol 8 2009 329 333
36. C.R. Mehren, and R. Gniadecki Dose-creep of infliximab during psoriasis treatment: an observational study Acta Derm Venereol 2011 Nov 1 doi:10. 2340/00015555-1230. [Epub ahead of print]
37. A. Jamnitski, C.L. Krieckaert, M.T. Nurmohamed, M.H. Hart, B.A. Dijkmans, and L. Aarden Patients non-responding to etanercept obtain lower etanercept concentrations compared with responding patients Ann Rheum Dis 71 2012 88 91
38. K. Papp, J. Crowley, J.P. Ortonne, J. Leu, M. Okun, and S.R. Gupta Adalimumab for moderate to severe chronic plaque psoriasis: efficacy and safety of retreatment and disease recurrence following withdrawal from therapy Br J Dermatol 164 2011 434 441
39. K.B. Gordon, A.B. Gottlieb, C.L. Leonardi, B.E. Elewski, A. Wang, and A. Jahreis Clinical response in psoriasis patients discontinued from and then reinitiated on etanercept therapy J Dermatolog Treat 17 2006 9 17 (Pubitemid 43247302)
40. A. Moore, K.B. Gordon, S. Kang, A. Gottlieb, B. Freundlich, and H.A. Xia A randomized, open-label trial of continuous versus interrupted etanercept therapy in the treatment of psoriasis J Am Acad Dermatol 56 2007 598 603 (Pubitemid 46400183)
41. J.P. Ortonne, A. Taieb, A.D. Ormerod, D. Robertson, J. Foehl, and R. Pedersen Patients with moderate-to-severe psoriasis recapture clinical response during re-treatment with etanercept Br J Dermatol 161 2009 1190 1195
42. R. Davies, J.B. Galloway, K.D. Watson, M. Lunt, D.P. Symmons, and K.L. Hyrich Venous thrombotic events are not increased in patients with rheumatoid arthritis treated with anti-TNF therapy: results from the British Society for Rheumatology Biologics Register Ann Rheum Dis 70 2011 1831 1834
43. N. Petitpain, N. Gambier, D. Wahl, I. Chary-Valckenaere, D. Loeuille, and P. Gillet Arterial and venous thromboembolic events during anti-TNF therapy: a study of 85 spontaneous reports in the period 2000-2006 Biomed Mater Eng 19 2009 355 364
44. A. Makol, M. Grover, C. Guggenheim, and H. Hassouna Etanercept and venous thromboembolism: a case series J Med Case Reports 4 2010 12
45. L.A. Korswagen, G.M. Bartelds, C.L. Krieckaert, F. Turkstra, M.T. Nurmohamed, and D. van Schaardenburg Venous and arterial thromboembolic events in adalimumab-treated patients with antiadalimumab antibodies: a case series and cohort study Arthritis Rheum 63 2011 877 883
46. G.M. Bartelds, C.A. Wijbrandts, M.T. Nurmohamed, S. Stapel, W.F. Lems, and L. Aarden Anti-infliximab and anti-adalimumab antibodies in relation to response to adalimumab in infliximab switchers and anti-tumour necrosis factor naive patients: a cohort study Ann Rheum Dis 69 2010 817 821
47. A. Jamnitski, G.M. Bartelds, M.T. Nurmohamed, P.A. van Schouwenburg, D. van Schaardenburg, and S.O. Stapel The presence or absence of antibodies to infliximab or adalimumab determines the outcome of switching to etanercept Ann Rheum Dis 70 2011 284 288
48. K. Bendtzen Is there a need for immunopharmacologic guidance of anti-tumor necrosis factor therapies? Arthritis Rheum 63 2011 867 870
49. T. Pham, H. Bachelez, J.M. Berthelot, J. Blacher, Y. Bouhnik, and P. Claudepierre TNF alpha antagonist therapy and safety monitoring Joint Bone Spine 78 Suppl 1 2011 15 185
50. P.J. Charles, R.J. Smeenk, J. De Jong, M. Feldmann, and R.N. Maini Assessment of antibodies to double-stranded DNA induced in rheumatoid arthritis patients following treatment with infliximab, a monoclonal antibody to tumor necrosis factor alpha: findings in open-label and randomized placebo-controlled trials Arthritis Rheum 43 2000 2383 2390
51. L. De Rycke, E. Kruithof, N. Van Damme, I.E. Hoffman, N. Van den Bossche, and F. Van den Bosch Antinuclear antibodies following infliximab treatment in patients with rheumatoid arthritis or spondylarthropathy Arthritis Rheum 48 2003 1015 1023 (Pubitemid 36418243)
52. N. Shakoor, M. Michalska, C.A. Harris, and J.A. Block Drug-induced systemic lupus erythematosus associated with etanercept therapy Lancet 359 2002 579 580 (Pubitemid 34178442)
53. L. De Rycke, D. Baeten, E. Kruithof, F. Van den Bosch, E.M. Veys, and F. De Keyser Infliximab, but not etanercept, induces IgM anti-double-stranded DNA autoantibodies as main antinuclear reactivity: biologic and clinical implications in autoimmune arthritis Arthritis Rheum 52 2005 2192 2201 (Pubitemid 40994342)
54. M. Debandt, O. Vittecoq, V. Descamps, X. Le Loet, and O. Meyer Anti-TNF-alpha-induced systemic lupus syndrome Clin Rheumatol 22 2003 56 61
55. M. De Bandt, J. Sibilia, X. Le Loet, S. Prouzeau, B. Fautrel, and C. Marcelli Systemic lupus erythematosus induced by anti-tumour necrosis factor alpha therapy: a French national survey Arthritis Res Ther 7 2005 R545 R551
56. D.A. Wetter, and M.D. Davis Lupus-like syndrome attributable to anti-tumor necrosis factor alpha therapy in 14 patients during an 8-year period at Mayo Clinic Mayo Clin Proc 84 2009 979 984
57. C. Eriksson, S. Engstrand, K.G. Sundqvist, and S. Rantapaa-Dahlqvist Autoantibody formation in patients with rheumatoid arthritis treated with anti-TNF alpha Ann Rheum Dis 64 2005 403 407 (Pubitemid 40283050)
58. A.E. Pink, A. Fonia, M.H. Allen, C.H. Smith, and J.N. Barker Antinuclear antibodies associate with loss of response to antitumour necrosis factor-alpha therapy in psoriasis: a retrospective, observational study Br J Dermatol 162 2010 780 785
59. O. Golberg, J.E. Osborne, and P.E. Hutchinson Antinuclear antibodies associate with loss of response to antitumour necrosis factor-alpha therapy in psoriasis but do not necessarily predict treatment failure Br J Dermatol 164 2011 459 460
60. S. Vermeire, M. Noman, G. Van Assche, F. Baert, K. Van Steen, and N. Esters Autoimmunity associated with anti-tumor necrosis factor alpha treatment in Crohn's disease: a prospective cohort study Gastroenterology 125 2003 32 39 (Pubitemid 36799104)
61. J.H. Hoffmann, M. Hartmann, A.H. Enk, and E.N. Hadaschik Autoantibodies in psoriasis as predictors for loss of response and anti-infliximab antibody induction Br J Dermatol 165 2011 1355 1358
62. A. Cassinotti, and S. Travis Incidence and clinical significance of immunogenicity to infliximab in Crohn's disease: a critical systematic review Inflamm Bowel Dis 15 2009 1264 1275
63. Infliximab - European Summary of Product Characteristics: EMEA 26/07/2011. Report No.: Remicade - EMEA/H/C/000240 - II/0155.
64. Adalimumab - European Summary of Product Characteristics: EMEA 18/03/2011. Report No.: Humira - EMEA/H/C/000481 - II/0081/G.
65. Etanercept - European Summary of Product Characteristics: EMEA 24/08/2011. Report No.: Enbrel - EMEA/H/C/000262 - II/126.
66. Ustekinumab - European Summary of Product Characteristics. 29/07/2011. Report No.: Stelara - EMEA/H/C/000958 - IA/0016/G.